SEC 8-K News



2024-12-09 17:04:00

Cumberland Pharmaceuticals Inc. has announced the FDA approval of a supplemental New Drug Application for its product Acetadote®. The approval pertains to a new dosing regimen that simplifies its administration by combining the first two doses into a single infusion. Acetadote is used intravenously to prevent or reduce liver damage from an overdose of acetaminophen.

  • Cumberland Pharmaceuticals Inc.
  • Acetadote®
  • FDA (U.S. Food and Drug Administration)
  • John Hamm (Chief Financial Officer)